_PRIVATE_LIMITED_383653.webp)
Cyamopsis Biotech (India) Profile
Key Indicators
- Authorised Capital ₹ 7.30 Cr
as on 16-11-2024
- Paid Up Capital ₹ 7.26 Cr
as on 16-11-2024
- Company Age 12 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 30.25 Cr
as on 16-11-2024
- Revenue 8.39%
(FY 2023)
- Profit 113.82%
(FY 2023)
- Ebitda 904.72%
(FY 2023)
- Net Worth 30.10%
(FY 2023)
- Total Assets 18.68%
(FY 2023)
About Cyamopsis Biotech (India)
The Corporate was formerly known as Dada Ganpati Guar Products Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.30 Cr and a paid-up capital of Rs 7.26 Cr.
The company currently has active open charges totaling ₹30.25 Cr.
Raj Jalan, Pankaj Khemka, Anju Jalan, and One other member serve as directors at the Company.
- CIN/LLPIN
U01136HR2012PTC045395
- Company No.
045395
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Mar 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Sirsa, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Cyamopsis Biotech (India) Private Limited offer?
Cyamopsis Biotech (India) Private Limited offers a wide range of products and services, including Coir and Agro Products, Natural Gum, Cattle Feed, Guar Meal, Flavours & Aromatics, Food Stabilizer, Bird Food, Poultry & Animal Food, Agro Waste, Guar Splits, Roasted Guar Korma.
Who are the key members and board of directors at Cyamopsis Biotech (India)?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raj Jalan  | Director | 14-Mar-2012 | Current |
| Pankaj Khemka | Director | 14-Mar-2012 | Current |
| Anju Jalan | Director | 14-Mar-2012 | Current |
| Suresh Singla | Director | 14-Mar-2012 | Current |
Financial Performance of Cyamopsis Biotech (India).
Cyamopsis Biotech (India) Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 8.39% increase. The company also saw a substantial improvement in profitability, with a 113.82% increase in profit. The company's net worth Soared by an impressive increase of 30.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cyamopsis Biotech (India)?
In 2023, Cyamopsis Biotech (India) had a promoter holding of 49.23% and a public holding of 50.77%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Ohm Entertainment Private LimitedActive 17 years 2 months
Raj Jalan and Pankaj Khemka are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Jul 2024 | ₹15.00 Cr | Open |
Axis Bank Limited Creation Date: 16 May 2024 | ₹1.68 Cr | Open |
Axis Bank Limited Creation Date: 05 Apr 2024 | ₹1.00 M | Open |
How Many Employees Work at Cyamopsis Biotech (India)?
Cyamopsis Biotech (India) has a workforce of 4 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cyamopsis Biotech (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cyamopsis Biotech (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
